Biotech · Private company
Clarity Pharmaceuticals Ltd
Track this companyFree. Adds Clarity Pharmaceuticals Ltd to your Dealase workspace and tells you when its record changes.
Clinical trials83 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- 64Cu-SAR-bisPSMAPhase 3 · Prostate CancerClinicalTrials.gov · fetched Nov 12, 2026
- 64Cu-SAR-BBNPhase 2 · Biochemical Recurrence of Malignant Neoplasm of ProstateClinicalTrials.gov · fetched Nov 12, 2026
- 64Cu-SAR-BBNPhase 2 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- 64Cu-SAR-bisPSMAPhase 2 · Prostatic Neoplasms, Castration-ResistantClinicalTrials.gov · fetched Nov 12, 2026
- 64Cu-SAR-bisPSMAPhase 2 · Biochemical Recurrence of Malignant Neoplasm of ProstateClinicalTrials.gov · fetched Nov 12, 2026
- 64Cu-SARTATEPhase 2 · NeuroblastomaClinicalTrials.gov · fetched Nov 12, 2026
- 67Cu-SAR-BBNPhase 2 · Prostatic NeoplasmsClinicalTrials.gov · fetched Nov 12, 2026
- 67Cu-SAR-bisPSMAPhase 2 · Prostatic Neoplasms, Castration-ResistantClinicalTrials.gov · fetched Nov 12, 2026
- 67Cu-SARTATEPhase 2 · NeuroblastomaClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials8
- 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate CancerPHASE3 · ACTIVE_NOT_RECRUITING · started May 16, 2025ClinicalTrials.gov NCT06970847 · fetched Nov 12, 2026
- Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical ProstatectomyPHASE3 · RECRUITING · started Dec 21, 2023ClinicalTrials.gov NCT06056830 · fetched Nov 12, 2026
- 64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)PHASE1_PHASE2 · TERMINATED · started Jun 15, 2023ClinicalTrials.gov NCT05633160 · fetched Nov 12, 2026
- 64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)PHASE2 · COMPLETED · started Sep 19, 2022ClinicalTrials.gov NCT05407311 · fetched Nov 12, 2026
- 64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)PHASE1_PHASE2 · COMPLETED · started Apr 11, 2022ClinicalTrials.gov NCT05249127 · fetched Nov 12, 2026
- 64Cu-SAR-bisPSMA Positron Emission Tomography of Patients With Known or Suspected Prostate CancerPHASE1_PHASE2 · UNKNOWN · started Mar 28, 2022ClinicalTrials.gov NCT05286840 · fetched Nov 12, 2026
- 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)PHASE1_PHASE2 · RECRUITING · started Aug 11, 2021ClinicalTrials.gov NCT04868604 · fetched Nov 12, 2026
- 67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory NeuroblastomaPHASE1_PHASE2 · TERMINATED · started Aug 18, 2020ClinicalTrials.gov NCT04023331 · fetched Nov 12, 2026